Nuwellis earnings date
Want to see NUWE full AI Analyst Report?
Nuwellis (NUWE) Q3 2026 Earnings Report
NUWE Q3 2026 EPS Results
- Actual EPS
- -$5.81
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- $176.40
NUWE Q3 2026 Revenue Results
- Actual Revenue
- $2.21M
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- -0.23%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
Nuwellis's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive. Management highlighted double-digit year-to-date revenue growth, an 88% increase in console sales, pediatric growth, substantial gross-margin expansion, lower operating expenses, regulatory progress, new commercial agreements, a developing 2027 product pipeline, and strengthened liquidity. These positives were partially offset by flat third-quarter revenue, lower quarterly console sales, a continued operating loss, a net loss, and challenging second-half comparisons.
Nuwellis said it expects to launch the pediatric Zorro-Flow external urine collection system in the first quarter of 2027, Aquadex SmartView has an expected launch in the first quarter of 2027, and it expects the Aquadex Pressure IQ to launch in the first half of 2027; if the FDA clears its 510(k) application, the expanded Aquadex pediatric indication would serve patients weighing as low as 5 kilograms and above. The company said its $8.3 million in cash and cash equivalents provides runway through the second quarter of 2027, its AtriAmp pipeline positions it well for growth as it moves into 2027, and its financial priorities remain increasing recurring circuit revenue, reducing cash utilization and directing capital toward commercial and development programs with the greatest potential to create value.
- Improved Operating PerformanceThird-quarter gross margin expanded by 430 basis points, operating expenses declined 13% year-over-year, and operating loss improved 24% year-over-year, reflecting disciplined spending and improved operating efficiency.
- Year-to-Date Revenue GrowthRevenue for the first nine months of 2026 was $6.6 million, an increase of 13% from the prior-year period, driven by growth in U.S. circuit and console sales.
- Expanded Gross MarginThird-quarter gross profit was approximately $1.5 million, with gross margin increasing to 70% from 65% in the prior-year quarter. The improvement was driven by higher circuit and console average selling prices, favorable product mix, and benefits from the contract manufacturing model.
- Reduced Operating ExpensesThird-quarter operating expenses were approximately $3.6 million, down from approximately $4.1 million in the prior-year quarter and approximately $4.7 million in the second quarter of 2026. The year-over-year decrease primarily reflected reductions in administrative costs and lower sales-related compensation.
- Strong Console Sales Growth Year to DateNuwellis sold 32 Aquadex consoles during the first nine months of 2026 compared with 17 in the prior-year period, an 88% increase.
- Underlying Business MomentumAlthough the third-quarter comparison included an approximately $400,000 benefit from accumulated back orders fulfilled in the prior-year quarter, management stated that the underlying performance grew 20%.
- Pediatric Business GrowthPediatric net sales increased 20% in the third quarter and 26% during the first nine months of 2026 compared with the respective prior-year periods. Management identified pediatrics as the company's growth driver.
- ULTRA-Peds Registry PublicationResults from the ULTRA-Peds Registry were accepted for publication in Pediatric Nephrology. The multicenter study evaluated 91 pediatric patients treated with Aquadex across seven children's hospitals; 62% weighed less than 10 kilograms, 87% survived their Aquadex treatment course, and 86.5% of procedures were completed without interruption.
- FDA 510(k) Submission for Expanded Pediatric IndicationOn November 5, Nuwellis submitted a 510(k) application to expand the Aquadex SmartFlow indication from patients weighing 20 kilograms and above to patients weighing as little as 5 kilograms and above. The company stated that ULTRA-Peds data supported its FDA pre-submission discussions and regulatory strategy.
- AtriAmp Commercial AgreementNuwellis entered into a co-promotion and distribution agreement with Atrility Medical for the AtriAmp postoperative cardiac rhythm monitoring device. The company reported multiple joint sales and service calls, encouraging customer response, and a growing pipeline of accounts actively in process.
- Zorro-Flow Distribution RightsNuwellis secured exclusive U.S. distribution rights for the pediatric Zorro-Flow external urine collection system and expects to launch the product in the first quarter of 2027. Management stated that the agreement expands the product portfolio by leveraging the existing commercial team and customer relationships without significant capital required.
- 2027 Product Development PipelineAquadex SmartView is under development with an expected launch in the first quarter of 2027, and Aquadex Pressure IQ is expected to launch in the first half of 2027. Clarity Prime development is advancing, and the company is evaluating additional applications for the acquired automated kidney function monitoring technology.
- Expanded Clinical and Commercial EngagementNuwellis participated in four medical conferences in October covering pediatrics, critical care, and heart failure, including the American Society of Nephrology's Kidney Week. The company stated that these meetings enabled direct engagement with clinicians and a focus on generating new accounts and increasing Aquadex utilization.
- Strengthened Balance SheetNuwellis ended the quarter with approximately $8.3 million in cash and cash equivalents, providing runway through the second quarter of 2027. During the quarter, the company raised $3.4 million in gross proceeds through a registered direct offering, received $3.3 million from the cash exercise of warrants, and received $1.4 million in net proceeds from its at-the-market program.
- Capital Discipline and Strategic InvestmentManagement reiterated its focus on increasing recurring circuit revenue, reducing cash utilization, and directing capital toward commercial and development programs with the greatest potential for long-term growth, while continuing to invest in priority initiatives.
NUWE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | ―- | -472.5 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | ―-5.81 | 176.4 | -103.29% (-182.21) | |
| Aug 13, 2026 | 2026 (Q2) | -214.20-239.76 | -19211.85 | 98.75% (+18972.09) | |
| May 12, 2026 | 2026 (Q1) | -315.00-658.35 | -9128.7 | 92.79% (+8470.35) | |
| Mar 10, 2026 | 2025 (Q4) | -491.40-472.50 | -5821.2 | 91.88% (+5348.70) | |
| Nov 12, 2025 | 2025 (Q3) | ―176.40 | 23020.2 | -99.23% (-22843.80) | |
| Aug 14, 2025 | 2025 (Q2) | -5953.50-19211.85 | -249385.5 | 92.30% (+230173.65) | |
| May 13, 2025 | 2025 (Q1) | -5953.50-9128.70 | -277830 | 96.71% (+268701.30) | |
| Mar 11, 2025 | 2024 (Q4) | -5688.90-5821.20 | -1037232 | 99.44% (+1031410.80) | |
| Nov 11, 2024 | 2024 (Q3) | -16934.4023020.20 | -838120.5 | 102.75% (+861140.70) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

